{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05750589",
            "orgStudyIdInfo": {
                "id": "IRX-2022-001"
            },
            "organization": {
                "fullName": "iRenix Medical, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections",
            "officialTitle": "Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Pain and Corneal Epitheliopathy",
            "acronym": "COMFORT",
            "therapeuticArea": [
                "Ophthalmology"
            ],
            "study": "safety-and-tolerability-of-irx-in-patients-receiving-intravitreal-injections"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-22",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-17",
            "studyFirstSubmitQcDate": "2023-02-28",
            "studyFirstPostDateStruct": {
                "date": "2023-03-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-03-01",
            "lastUpdatePostDateStruct": {
                "date": "2023-03-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "iRenix Medical, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections."
        },
        "conditionsModule": {
            "conditions": [
                "Retinal Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Subjects will be randomized to IRX-101 or Providone-Iodine",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Treatment assignment will be unknown (or masked) to the study subjects, the evaluating physician, the Sponsor and its agents (with the exception of personnel performing randomization, unmasked drug accountability study monitors, and corporate compliance staff). The treating physician will be unmasked.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 240,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "IRX-101",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects randomized to IRX-101 will receive the investigational product, IRX-101.",
                    "interventionNames": [
                        "Drug: IRX-101"
                    ]
                },
                {
                    "label": "5% Povidone-iodine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects randomized to this arm will receive the standard of care, Providone-iodine, at a concentration of 5%.",
                    "interventionNames": [
                        "Drug: Providone-Iodine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "IRX-101",
                    "description": "IRX-101 is a novel ocular anti-septic",
                    "armGroupLabels": [
                        "IRX-101"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Providone-Iodine",
                    "description": "5% Providone-Iodine",
                    "armGroupLabels": [
                        "5% Povidone-iodine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Assessment of post-intravitreal injection eye pain",
                    "description": "Demonstrate the superiority of IRX-101 compared to PI in terms of reducing patient-reported post-intravitreal injection eye pain; pain will be assessed using the visual analog pain scale, a validated patient-reported outcome measure (questionnaire) for assessing patient's subjective pain and discomfort",
                    "timeFrame": "Demonstrate a reduction in mean 1-hr post-injection pain scores"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in post-IVT corneal epitheliopathy as evaluated by corneal fluorescein staining scores",
                    "description": "Demonstrate the superiority of IRX-101 compared to PI in terms of reducing corneal epitheliopathy / corneal fluorescein staining post-intravitreal injection; corneal staining will be obtained using validated Oxford Corneal Staining scale of 0 (no staining) to 5 (maximal corneal staining)",
                    "timeFrame": "Immediately following intraviteral injection"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Capable of giving informed consent\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, \u2265 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyes\n\nExclusion Criteria:\n\n1. Current or past diagnosis of endophthalmitis\n2. Current diagnosis of uveitis\n3. Monocular patients (vision 20/100 or worse in one eye) who are receiving injections in the better seeing eye\n4. Current use of viscous lidocaine products for ocular anesthesia prior to IVT\n5. Currently receiving intravitreal steroid injections\n6. Concurrent participation in another clinical trial\n7. Females who are pregnant, planning to become pregnant or lactating",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stephen Smith, MD",
                    "role": "CONTACT",
                    "phone": "650-785-1316",
                    "email": "stephen@irenix.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Stephen Smith, MD",
                    "affiliation": "Founder",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "R. Gary Lane, II MD",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78240",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Francisco Angueira",
                            "role": "CONTACT",
                            "phone": "800-833-5921"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012164",
                    "term": "Retinal Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M14999",
                    "name": "Retinal Diseases",
                    "asFound": "Retinal Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10488",
                    "name": "Iodine",
                    "relevance": "LOW"
                },
                {
                    "id": "M229695",
                    "name": "Cadexomer iodine",
                    "relevance": "LOW"
                },
                {
                    "id": "M14088",
                    "name": "Povidone-Iodine",
                    "relevance": "LOW"
                },
                {
                    "id": "M14087",
                    "name": "Povidone",
                    "relevance": "LOW"
                },
                {
                    "id": "M4215",
                    "name": "Anti-Infective Agents, Local",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "BlSubst",
                    "name": "Blood Substitutes"
                }
            ]
        }
    },
    "hasResults": false
}